Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients - Collins, P. W.; Quon, D. V. K.; Makris, M.; Chowdary, P.; Kempton, C. L.; Apte, S. J.; Ramanan, M. V.; Hay, C. R. M.; Drobic, B.; Hua, Y.; Babinchak, T. J.; Gomperts, E. D. (Haemophilia : the official journal of the World Federation of Hemophilia, 2018)
Keywords: Adolescent; Adult; Antibodies; Area Under Curve; Blood Coagulation Factor Inhibitors - blood; Coagulation factors; Dose-Response Relationship, Drug; Double-Blind Method; efficacy; Factor IX - adverse effects; Factor IX - pharmacokinetics; Factor IX - therapeutic use; Factor IX deficiency; haemophilia B; Half-Life; Headache; Headache - etiology; Hemophilia; Hemophilia B - drug therapy; Hemophilia B - pathology; Hemorrhage - prevention & control; Humans; IB1001; Immunoglobulins; Male; Pharmacokinetics; Prophylaxis; recombinant factor IX; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; ROC Curve; Safety; Severity of Illness Index; Treatment Outcome; Young Adult; pharmacokinetics; haemophilia B; recombinant factor IX; IB1001; safety; efficacy